Compare Nutanix Inc (NTNX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Novo Nordisk A/S — how do they compare? Nutanix Inc trades at $74.65 (market cap $19.78B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 8.4× Nutanix Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Novo Nordisk A/S for 116 Days on average.
| NTNX | NVO | |
|---|---|---|
Market Cap | $19.78B | $165.31B |
Volume | 1,717,619 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $73.42 | $63.98 |
52-Week Low | $34.41 | $35.29 |
Typical Hold Time | 17 Days | 116 Days |
Enterprise Value | $18.94B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $73.98, up 0.76% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust profitability with a net income margin of 52.81% for 2026 and is recognized as a leader in multiple Gartner Magic Quadrant reports, highlighting its competitive strength in hybrid cloud infrastructure.
The outlook is positive with analyst consensus favoring a buy rating and a $76.11 price target, though risks include high valuation multiples like a 46.22 EV/EBITDA and negative ROE. Revenue growth and external storage expansion present opportunities, but investors should monitor execution against guidance and market volatility.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
